PharmatrophiX (PTX) is a privately held, clinical-stage biopharmaceutical company focused on the
development of disease-modifying small molecule drugs targeting mechanisms underlying
neurodegenerative and other disorders.
PTX is operated as a virtual biotech company in Menlo Park, CA executing drug development
through contracted work. This virtual model is recognized as an effective way of minimizing
overhead costs while efficiently achieving drug development milestones.
Corporate and drug development funding has been provided by private investors and peer-reviewed grants.